Abiopharma

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Spider-Man: Beyond the Spider-Verse – Everything We Know So Far

11-K (Annual Report of Employee Stock Plans) SEC Filing

New Form DEFA14A - Rein Therapeutics, Inc. Filed: 2025-06-24 AccNo: 0001193125-25-145714 Size: 16 KB

New Form 8-K - MIRA PHARMACEUTICALS, INC. Filed: 2025-06-24 AccNo: 0001641172-25-016285 Size: 209 KB Item 8.01: Other Events

New Form 144 - AGIOS PHARMACEUTICALS, INC. Filed: 2025-06-24 AccNo: 0001900772-25-000002 Size: 4 KB

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

New Form 8-K - KINETA, INC./DE Filed: 2025-06-24 AccNo: 0000950170-25-089443 Size: 271 KB Item 5.07: Submission of Matters to a Vote of Security Holders Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 11-K - EXACT SCIENCES CORP Filed: 2025-06-24 AccNo: 0001124140-25-000051 Size: 216 KB

New Form 8-K - Rein Therapeutics, Inc. Filed: 2025-06-24 AccNo: 0001193125-25-145711 Size: 136 KB Item 8.01: Other Events

Forte Biosciences Inc - Forte Biosciences Announces Proposed Public Offering

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Forte Biosciences Announces Proposed Public Offering

New Form 4 - Merus N.V. Filed: 2025-06-24 AccNo: 0000950170-25-089442 Size: 8 KB

Notification from cbdMD, Inc.